EDSA vs. CLLS, CLSD, ZIVO, INZY, PMVP, OKUR, OCX, ANEB, TNYA, and GANX
Should you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Cellectis (CLLS), Clearside Biomedical (CLSD), ZIVO Bioscience (ZIVO), Inozyme Pharma (INZY), PMV Pharmaceuticals (PMVP), OnKure Therapeutics (OKUR), OncoCyte (OCX), Anebulo Pharmaceuticals (ANEB), Tenaya Therapeutics (TNYA), and Gain Therapeutics (GANX). These companies are all part of the "pharmaceutical products" industry.
Edesa Biotech vs.
Edesa Biotech (NASDAQ:EDSA) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, community ranking, profitability, risk, valuation, institutional ownership and dividends.
5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 25.0% of Edesa Biotech shares are owned by company insiders. Comparatively, 16.4% of Cellectis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Edesa Biotech has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.27, suggesting that its stock price is 227% more volatile than the S&P 500.
In the previous week, Cellectis had 2 more articles in the media than Edesa Biotech. MarketBeat recorded 4 mentions for Cellectis and 2 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 1.25 beat Cellectis' score of -0.20 indicating that Edesa Biotech is being referred to more favorably in the media.
Edesa Biotech has a net margin of 0.00% compared to Cellectis' net margin of -234.39%. Cellectis' return on equity of -74.55% beat Edesa Biotech's return on equity.
Edesa Biotech has higher earnings, but lower revenue than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks.
Edesa Biotech currently has a consensus target price of $21.00, indicating a potential upside of 743.37%. Cellectis has a consensus target price of $7.00, indicating a potential upside of 434.35%. Given Edesa Biotech's higher possible upside, equities analysts plainly believe Edesa Biotech is more favorable than Cellectis.
Cellectis received 383 more outperform votes than Edesa Biotech when rated by MarketBeat users. However, 77.78% of users gave Edesa Biotech an outperform vote while only 65.03% of users gave Cellectis an outperform vote.
Summary
Cellectis beats Edesa Biotech on 10 of the 16 factors compared between the two stocks.
Get Edesa Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edesa Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:EDSA) was last updated on 3/26/2025 by MarketBeat.com Staff
